Background and Purpose: The goal of the study is to compare the efficacy of single Rinderon(superscript ®) injection between intranasal route and intramuscular route. Methods: From January 2005 to December 2006, forty volunteers from outpatients were enrolled into the study. They were all diagnosed as allergic rhinitis without any other underlying disease, randomly categorized into two groups: intranasal injection group or intramuscular injection group, with 20 patients in each. A dosage of 25mg Rinderon(superscript ®) in liquid form was injected to each subject via different route according to the group he/she was in, at one week after cessation of any medication for allergic rhinitis. Serum cortisol level was measured before and at 2 weeks, 4 weeks after injection. The questionnaire of symptoms and nasal mucosa biopsy were obtained before and at 4 weeks after injection to identify the effect. Results: In intranasal injection group, 15 (75%) patients had significant symptomatic improvement, whereas in intramuscular injection group, 11 (55%) patients significantly improved. The difference between 2 groups was measured by Chi-square method and showed no significant difference (P value>0.05). The depression of serum cortisol level was statistically significant in each group at 2 weeks, 4 weeks after the injection, compared to their pre-injection level (p<0.05, all). However, the depression level between 2 groups does not significantly differ (p>0.05). Even the serum cortisol level was significantly depressed after the injection in both groups, the value was still within the normal fluctuation rang, and afterward returned to normal level no later than 4 weeks. The rebound phenomenon of serum cortisol level after iatrogenic depression measured at 1 month after injection revealed no significant difference between the two groups (p>0.05). Conclusion: In addition to the given routes of oral intake, nasal spray, and intramuscular injection, intranasal injection of single dose steroid is also an effective and safe modality in the treatment of allergic rhinitis.
Background and Purpose: The goal of the study is to compare the efficacy of single Rinderon(superscript ®) injection between intranasal route and intramuscular route. Methods: From January 2005 to December 2006, forty volunteers from outpatients were enrolled into the study. They were all diagnosed as allergic rhinitis without any other underlying disease, randomly categorized into two groups: intranasal injection group or intramuscular injection group, with 20 patients in each. A dosage of 25mg Rinderon(superscript ®) in liquid form was injected to each subject via different route according to the group he/she was in, at one week after cessation of any medication for allergic rhinitis. Serum cortisol level was measured before and at 2 weeks, 4 weeks after injection. The questionnaire of symptoms and nasal mucosa biopsy were obtained before and at 4 weeks after injection to identify the effect. Results: In intranasal injection group, 15 (75%) patients had significant symptomatic improvement, whereas in intramuscular injection group, 11 (55%) patients significantly improved. The difference between 2 groups was measured by Chi-square method and showed no significant difference (P value>0.05). The depression of serum cortisol level was statistically significant in each group at 2 weeks, 4 weeks after the injection, compared to their pre-injection level (p<0.05, all). However, the depression level between 2 groups does not significantly differ (p>0.05). Even the serum cortisol level was significantly depressed after the injection in both groups, the value was still within the normal fluctuation rang, and afterward returned to normal level no later than 4 weeks. The rebound phenomenon of serum cortisol level after iatrogenic depression measured at 1 month after injection revealed no significant difference between the two groups (p>0.05). Conclusion: In addition to the given routes of oral intake, nasal spray, and intramuscular injection, intranasal injection of single dose steroid is also an effective and safe modality in the treatment of allergic rhinitis.
為了持續優化網站功能與使用者體驗,本網站將Cookies分析技術用於網站營運、分析和個人化服務之目的。
若您繼續瀏覽本網站,即表示您同意本網站使用Cookies。